The role of prostate-specific antigen in light of new scientific evidence - Abstract

OBJECTIVE: Review the scientific evidence acquired in recent years on Prostate-Specific Antigen (PSA).

ACQUISITION OF EVIDENCE: Analysis of the available evidence on the current role of PSA, according to a panel of experts who recorded their experience on the subject.

SUMMARY OF THE EVIDENCE: Currently, PSA cannot be considered solely an indicator of the presence or absence of prostate cancer. Rather, the determination of PSA assists the urologist in indicating the most appropriate treatment for a patient with benign prostatic hypertrophic (BPH), as well as in suspecting a prostatic tumour when the PSA reading increases >0,3ng/ml, in patients treated with 5-alpha-reductase inhibitor, over the reading achieved at six months of having initiated this treatment. Moreover, PSA is a key factor in the follow-up of patients with prostate adenocarcinoma who undergo surgery, radiation therapy or minimally invasive techniques. PSA helps to define biochemical recurrence, suggest the existence of a local or distal recurrence and propose or rule out adjuvant therapies.

CONCLUSIONS: New data on the current role of PSA in the management of patients treated for BPH and/or prostate cancer should be taken into account.

Written by:
Hernández C, Morote J, Miñana B, Cózar JM.   Are you the author?
Servicio de Urología, Hospital General Universitario Gregorio Marañón, Madrid, España.

Reference: Actas Urol Esp. 2013 Apr 19. pii: S0210-4806(13)00036-3.
doi: 10.1016/j.acuro.2013.01.009


PubMed Abstract
PMID: 23608183

UroToday.com Prostate Cancer Section

 

 

 

 

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe